注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Relmada Therapeutics Inc是一家临床阶段的生物技术公司。该公司专注于开发艾美沙酮(d-美沙酮,dextromethadone,REL-1017),一种N-甲基-D-天冬氨酸(NMDA)受体拮抗剂。该公司的主要候选产品艾美沙酮是一种新型化学实体(NCE),开发为一种用于治疗抑郁症、中枢神经系统(CNS)疾病和其他潜在适应症的快速作用的口服药物。该公司的主导项目REL-1017是一种新型NMDA受体(NMDAR)通道阻滞剂,优先靶向过度活跃的通道,同时维持生理性谷氨酸能神经传递,并且正在开发用于重度抑郁症(MDD)的辅助或单一疗法。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Maged S. Shenouda | 60 | 2020 | Chief Financial Officer |
Paul E. Kelly | 67 | 2015 | Director |
Dan Iosifescu | - | 2020 | Member of Scientific Advisory Board |
John Glasspool | 61 | 2019 | Independent Director |
Charles E. Inturrisi | - | - | Member of Scientific Advisory Board |
Stephen M. Stahl | - | 2020 | Member of Scientific Advisory Board |
Sergio Traversa | 64 | 2012 | CEO & Director |
Maurizio Fava | - | 2017 | Member of Scientific Advisory Board |
Charles J. Casamento | 79 | 2015 | Independent Chairman of the Board |
Thomas P. Laughren | - | 2020 | Member of Scientific Advisory Board |
Luca Pani | - | 2020 | Member of Scientific Advisory Board |
Sanjay Johan Mathew | - | 2020 | Member of Scientific Advisory Board |
Fabiana Fedeli | 53 | 2023 | Independent Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核